Healthcare / Pharmaceutical RetailersTokyo
$3300.00
+30.00 (+0.91%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $3.2B · quality 70.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
56/100
C
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$73.7B
P/E
23.1x
↑EV/EBITDA
4.7x
↓ROE
4.3%
↑Gross Margin
23.2%
↓Debt/Equity
0.15
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+1.0%
FCF CAGR
+10.8%
FCF margin
1.1%
FCF / Net income
0.66x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $287.82B · net income $4.88B · FCF $3.22B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $287.82B | $287.82B | $285.96B | $281.87B | $279.46B |
| Net Income | $4.88B | $4.88B | $4.71B | $4.18B | $4.83B |
| EBITDA | $11.36B | $11.36B | $11.49B | $10.96B | $12.16B |
| EPS | 218.48 | 218.48 | 210.79 | 186.85 | 216.07 |
| Gross Margin | 23.2% | 23.2% | 23.0% | 22.7% | 22.6% |
| Operating Margin | 2.6% | 2.6% | 2.7% | 2.3% | 2.8% |
| Net Margin | 1.7% | 1.7% | 1.6% | 1.5% | 1.7% |
| Balance Sheet | |||||
| Debt/Equity | 0.15 | 0.15 | 0.15 | 0.18 | 0.22 |
| Current Ratio | 1.54 | 1.54 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $3.22B | $3.22B | $1.02B | $4.11B | $2.37B |
| Returns | |||||
| ROE | 4.3% | 4.3% | 4.2% | 3.9% | 4.6% |
| Valuation | |||||
| P/E | 23.08 | 23.08 | 12.36 | 11.90 | 10.08 |
| EV/EBITDA | 4.73 | 4.73 | 3.42 | 2.81 | 2.69 |
| P/B | 0.64 | 0.64 | 0.52 | 0.46 | 0.47 |
| Growth & Yield | |||||
| Revenue Growth | 0.6% | 0.6% | 1.5% | 0.9% | — |
| EPS Growth | 3.6% | 3.6% | 12.8% | -13.5% | — |
| Dividend Yield | 3.0% | 3.0% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
10.3%
EPS terminal req.
$292.82
Spread vs growth
-6.6%
5Y implied EPS CAGR
10.2%
EPS terminal req.
$354.31
Spread vs growth
-6.5%
10Y implied EPS CAGR
10.1%
EPS terminal req.
$570.62
Spread vs growth
-6.4%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+22.0%
Start / end P/E
13.2x → 15.2x
EPS bridge
210.79 → 218.48
Residual
+0.5%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.